GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Emcure Pharmaceuticals Ltd

Emcure Pharma Q1 FY27 Consolidated Revenue at INR 25,804.47 million

RESULTS ▲ Positive Development MEDIUM RISK
📅 Filed on BSE: 06 Aug 2026, 01:51 PM IST  ·  BSE ID: 1bf630c9-efc2-4847-b89e-37a6189ad85f
View Original BSE Filing (PDF)
💡
In Simple Terms
Emcure Pharmaceuticals announced its latest financial performance, reporting INR 25,804.47 million in quarterly revenue.
🤖 AI Summary
  • Consolidated Revenue from operations reached INR 25,804.47 million for the quarter ended June 30, 2026.
  • Consolidated Profit for the period was INR 2,924.93 million for Q1 FY27.
  • Basic and Diluted Earnings per Share was INR 15.50 for the quarter ended June 30, 2026.
  • The Board of Directors approved the Unaudited Financial Results on August 06, 2026.
  • The results include 14 subsidiaries and 3 step-down subsidiaries, with limited review by B S R & Co. LLP.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Consolidated Revenue from operations
INR 25,804.47 million
22.85%
Consolidated Profit for the period
INR 2,924.93 million
36.18%
Basic EPS
INR 15.50
41.94%
Total Tax Expenses
INR 1,010.33 million
33.00%
Paid up equity share capital
INR 1,896.82 million
🏢 How This Affects the Company
📈
Business Impact
The company recorded consolidated revenue from operations of INR 25,804.47 million, indicating its sales performance for the quarter.
💰
Financial Impact
Consolidated Profit for the period was INR 2,924.93 million, directly impacting the company's earnings. Total expenses stood at INR 21,889.92 million.
⚠️
Risk Impact
The Limited Review Report notes that interim financial information of 14 subsidiaries and 3 step-down subsidiaries, representing total revenues of Rs. 1,523 million, were not reviewed.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected by the company's financial performance as reported in the unaudited consolidated results for Q1 FY27, reflecting the company's profitability and revenue generation.
🔍
Management Signal
The approval and disclosure of the unaudited financial results indicate management's routine compliance with SEBI Listing Regulations.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Q2 FY27 unaudited financial results — assess revenue and profit trends
Updates on the reviewed status of subsidiary financial information
Changes in employee benefit expenses and other operating costs
MEDIUM RISK The non-review of interim financial information for significant subsidiaries introduces an element of risk.
💡 Investor Takeaway
Emcure Pharmaceuticals reported Q1 FY27 consolidated revenue from operations of INR 25,804.47 million, an increase from INR 21,005.37 million in Q1 FY26. Consolidated profit for the period rose to INR 2,924.93 million from INR 2,147.93 million in the prior year comparable period.
⚖️ Strengths & Concerns

✅ Positives

  • Consolidated Revenue from operations for Q1 FY27 increased to INR 25,804.47 million, up from INR 21,005.37 million in Q1 FY26.
  • Consolidated Profit for the period increased to INR 2,924.93 million in Q1 FY27, compared to INR 2,147.93 million in Q1 FY26.

⚠️ Concerns

  • The Limited Review Report indicates interim financial information of 14 subsidiaries and 3 step-down subsidiaries, representing Rs. 1,523 million total revenue, were not reviewed.
  • Finance costs increased to INR 315.36 million in Q1 FY27 from INR 267.55 million in Q1 FY26.
📅 Company Track Record
Emcure Pharmaceuticals' Q1 FY27 consolidated revenue grew by 22.8% YoY to INR 25,804 million, as previously noted in the earnings presentation filed on August 06, 2026.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Emcure Pharmaceuticals' consolidated revenue from operations for Q1 FY27?
Emcure Pharmaceuticals reported a consolidated revenue from operations of INR 25,804.47 million for the quarter ended June 30, 2026.
What was Emcure Pharmaceuticals' consolidated profit for the period in Q1 FY27?
The consolidated profit for the period for Emcure Pharmaceuticals was INR 2,924.93 million for the quarter ended June 30, 2026.
What were the Basic and Diluted Earnings per Share for Emcure Pharmaceuticals in Q1 FY27?
Emcure Pharmaceuticals' Basic and Diluted Earnings per Share stood at INR 15.50 for the quarter ended June 30, 2026.
Which entities are included in Emcure Pharmaceuticals' unaudited consolidated financial results?
The unaudited consolidated financial results include Emcure Pharmaceuticals Limited (Parent), along with 19 subsidiaries and 6 step-down subsidiaries, totaling 26 entities.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.